These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 22395687)
21. Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy. Hayes D; Warren PS; McCoy KS; Sheikh SI J Pediatr Gastroenterol Nutr; 2015 May; 60(5):578-9. PubMed ID: 25688481 [TBL] [Abstract][Full Text] [Related]
22. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding. Cohen D; Raftery J BMJ; 2014 Feb; 348():g1445. PubMed ID: 24523379 [No Abstract] [Full Text] [Related]
23. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy. Hayes D; Long FR; McCoy KS; Sheikh SI Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273 [No Abstract] [Full Text] [Related]
24. Ivacaftor for patients with cystic fibrosis. Wainwright CE Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205 [TBL] [Abstract][Full Text] [Related]
25. Precision Medicine: At What Price? Ferkol T; Quinton P Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804 [No Abstract] [Full Text] [Related]
26. Basic research funding by philanthropic organizations: a case in point. Chignard M; Ramphal R Am J Respir Crit Care Med; 2013 Dec; 188(11):1376-8. PubMed ID: 24289783 [No Abstract] [Full Text] [Related]
27. Cystic fibrosis: a review of pathophysiology and current treatment recommendations. Peters S S D Med; 2014 Apr; 67(4):148-51, 153. PubMed ID: 24791377 [No Abstract] [Full Text] [Related]
29. Update in cystic fibrosis 2013. Jain M; Goss CH Am J Respir Crit Care Med; 2014 May; 189(10):1181-6. PubMed ID: 24832742 [No Abstract] [Full Text] [Related]
30. Game Changers. Ulster Med J; 2015 Oct; 84(3):218-9. PubMed ID: 26668427 [No Abstract] [Full Text] [Related]
31. 50 years ago in The Journal of Pediatrics: The use of N-acetylcysteine in the treatment of cystic fibrosis. Cantu-Gonzalez G J Pediatr; 2014 Oct; 165(4):721. PubMed ID: 25256050 [No Abstract] [Full Text] [Related]
32. The organoid architect. Sinha G Science; 2017 Aug; 357(6353):746-749. PubMed ID: 28839056 [No Abstract] [Full Text] [Related]
33. Sweat chloride is not a useful marker of clinical response to Ivacaftor. Barry PJ; Jones AM; Webb AK; Horsley AR Thorax; 2014 Jun; 69(6):586-7. PubMed ID: 24258833 [TBL] [Abstract][Full Text] [Related]
34. CFTR potentiators: not an open and shut case. Clancy JP Sci Transl Med; 2014 Jul; 6(246):246fs27. PubMed ID: 25101884 [TBL] [Abstract][Full Text] [Related]
35. Pricing for orphan drugs: will the market bear what society cannot? O'Sullivan BP; Orenstein DM; Milla CE JAMA; 2013 Oct; 310(13):1343-4. PubMed ID: 24084916 [No Abstract] [Full Text] [Related]
36. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
37. Cystic fibrosis--what are the prospects for a cure? Kumar S; Tana A; Shankar A Eur J Intern Med; 2014 Nov; 25(9):803-7. PubMed ID: 25447947 [TBL] [Abstract][Full Text] [Related]
38. Cystic fibrosis in an era of genomically guided therapy. Barrett PM; Alagely A; Topol EJ Hum Mol Genet; 2012 Oct; 21(R1):R66-71. PubMed ID: 22914736 [TBL] [Abstract][Full Text] [Related]